Overview

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals